In a meta-analysis of the six major trials on use of SGLT2 inhibitors in individuals with type 2 diabetes, those with diabetes and ASCVD had an 11% reduction in the HR for major CV events compared with placebo, an effect that was only marginally present in people without ASCVD [84]. Here, SLC5A2 is linked to atherosclerosis.